N-methylnicotinamide is an endogenous probe for evaluation of drugdrug interactions involving multidrug and toxin extrusions (MATE1 and MATE2-K)

Clinical Pharmacology and Therapeutics

Volumn 92, Issue 5, 2012, Pages 635-641

  Ito, S ^a   Kusuhara, H ^a   Kumagai, Y ^b   Moriyama, Y ^c   Inoue, K ^d   Kondo, T ^e   Nakayama, H ^e   Horita, S ^e   Tanabe, K ^e   Yuasa, H ^d   Sugiyama, Y ^f  

^a UNIVERSITY OF TOKYO   (Japan)

^b KITASATO UNIVERSITY HOSPITAL   (Japan)

^c OKAYAMA UNIVERSITY   (Japan)

^d NAGOYA CITY UNIVERSITY   (Japan)

^e TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^f RIKEN   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MULTIDRUG AND TOXIN EXTRUSION 1 PROTEIN; MULTIDRUG AND TOXIN EXTRUSION 2 K PROTEIN; N METHYLNICOTINAMIDE; ORGANIC CATION TRANSPORTER; PROTON; PYRIMETHAMINE; UNCLASSIFIED DRUG;

ADULT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG PROTEIN BINDING; EMBRYO; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; KIDNEY CLEARANCE; KIDNEY TUBULE EPITHELIUM; MALE; MEMBRANE VESICLE; MOLECULAR PROBE; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; URINARY EXCRETION;

ADULT; DRUG INTERACTIONS; HUMANS; KIDNEY; MALE; MICROVILLI; NIACINAMIDE; ORGANIC CATION TRANSPORT PROTEINS; PYRIMETHAMINE; YOUNG ADULT;

EID: 84867869728     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.138     Document Type: Article

References (30)

1. Giacomini, K.M. & Sugiyama, Y. Membrane transporters and drug response. In Goodman & Gilman's the Pharmacological Basis of Therapeutics 11th edn. (eds. Brunton LL, Lazo JS & Parker KL) 41-70 (McGraw-Hill, New York, 2005).
2. Wright, S.H. Role of organic cation transporters in the renal handling of therapeutic agents and xenobiotics. Toxicol. Appl. Pharmacol. 204, 309-319 (2005). (Pubitemid 40545233)
3. Nies, A.T., Koepsell, H., Damme, K. & Schwab, M. Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb. Exp. Pharmacol. 201, 105-167 (2011).
4. Giacomini, K.M. et al.; International Transporter Consortium. Membrane transporters in drug development. Nat. Rev. Drug Discov. 9, 215-236 (2010).
5. Fujita, T., Urban, T.J., Leabman, M.K., Fujita, K. & Giacomini, K.M. Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants. J. Pharm. Sci. 95, 25-36 (2006).
6. Otsuka, M., Matsumoto, T., Morimoto, R., Arioka, S., Omote, H. & Moriyama, Y. A human transporter protein that mediates the final excretion step for toxic organic cations. Proc. Natl. Acad. Sci. USA 102, 17923-17928 (2005). (Pubitemid 41798478)
7. Masuda, S. et al. Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J. Am. Soc. Nephrol. 17, 2127-2135 (2006). (Pubitemid 44141902)
8. Tanihara, Y., Masuda, S., Sato, T., Katsura, T., Ogawa, O. & Inui, K. Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem. Pharmacol. 74, 359-371 (2007). (Pubitemid 46890818)
9. Moriyama, Y., Hiasa, M., Matsumoto, T. & Omote, H. Multidrug and toxic compound extrusion (MATE)-type proteins as anchor transporters for the excretion of metabolic waste products and xenobiotics. Xenobiotica. 38, 1107-1118 (2008).
10. Terada, T. & Inui, K. Physiological and pharmacokinetic roles of H+/organic cation antiporters (MATE/SLC47A). Biochem. Pharmacol. 75, 1689-1696 (2008).
11. Tsuda, M., Terada, T., Mizuno, T., Katsura, T., Shimakura, J. & Inui, K. Targeted disruption of the multidrug and toxin extrusion 1 (mate1) gene in mice reduces renal secretion of metformin. Mol. Pharmacol. 75, 1280-1286 (2009).
12. Matsushima, S. et al. The inhibition of human multidrug and toxin extrusion 1 is involved in the drug-drug interaction caused by cimetidine. Drug Metab. Dispos. 37, 555-559 (2009).
13. Ito, S. et al. Potent and specific inhibition of mMate1-mediated efflux of type I organic cations in the liver and kidney by pyrimethamine. J. Pharmacol. Exp. Ther. 333, 341-350 (2010).
14. Ito, S., et al. Competitive inhibition of the luminal efflux by MATEs, but not basolateral uptake by OCT2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. J Pharmacol Exp Ther. 340, 393-403 (2012).
15. Li, M., Anderson, G.D. & Wang, J. Drug-drug interactions involving membrane transporters in the human kidney. Expert Opin. Drug Metab. Toxicol. 2, 505-532 (2006). (Pubitemid 46127070)
16. Kusuhara, H. et al. Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects. Clin. Pharmacol. Ther. 89, 837-844 (2011).
17. Maïza, A., Waldek, S., Ballardie, F.W. & Daley-Yates, P.T. Estimation of renal tubular secretion in man, in health and disease, using endogenous N-1-methylnicotinamide. Nephron 60, 12-16 (1992).
18. Dixon, J.S., Borg-Costanzi, J.M., Langley, S.J., Lacey, L.F. & Toon, S. The effect of renal function on the pharmacokinetics of ranitidine. Eur. J. Clin. Pharmacol. 46, 167-171 (1994). (Pubitemid 24101337)
19. Gorboulev, V. et al. Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 16, 871-881 (1997). (Pubitemid 27332696)
20. Hsyu, P.H., Gisclon, L.G., Hui, A.C. & Giacomini, K.M. Interactions of organic anions with the organic cation transporter in renal BBMV. Am. J. Physiol. 254, F56-F61 (1988).
21. Griffiths, D.A., Hall, S.D. & Sokol, P.P. Effect of 3?-azido-3?-deoxythymidine (AZT) on organic ion transport in rat renal brush border membrane vesicles. J. Pharmacol. Exp. Ther. 260, 128-133 (1992).
22. Yonezawa, A. & Inui, K. Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/ toxicodynamics and pharmacogenomics. Br. J. Pharmacol. 164, 1817-1825 (2011).
23. Ott, R.J., Hui, A.C., Yuan, G. & Giacomini, K.M. Organic cation transport in human renal brush-border membrane vesicles. Am. J. Physiol. 261, F443-F451 (1991).
24. Somogyi, A., Siebert, D. & Bochner, F. Determination of endogenous concentrations of N1-methylnicotinamide in human plasma and urine by highperformance liquid chromatography. Anal. Biochem. 187, 160-165 (1990). (Pubitemid 20157534)
25. Nakamura, T., Yonezawa, A., Hashimoto, S., Katsura, T. & Inui, K. Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. Biochem. Pharmacol. 80, 1762-1767 (2010).
26. Imamura, Y. et al. Prediction of fluoroquinolone-induced elevation in serum creatinine levels: a case of drug-endogenous substance interaction involving the inhibition of renal secretion. Clin. Pharmacol. Ther. 89, 81-88 (2011).
27. Busch, A.E. et al. Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol. Pharmacol. 54, 342-352 (1998). (Pubitemid 28368824)
28. Lowry, O.H., Rosebrough, N.J., Farr, A.L. & Randall, R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265-275 (1951).
29. Hasegawa, M. et al. Functional involvement of rat organic anion transporter 3 (rOat3; Slc22a8) in the renal uptake of organic anions. J. Pharmacol. Exp. Ther. 300, 746-753 (2002).
30. Opravil, M., Keusch, G. & Lüthy, R. Pyrimethamine inhibits renal secretion of creatinine. Antimicrob. Agents Chemother. 37, 1056-1060 (1993). (Pubitemid 23141320)